Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Andrew D. Chantry"'
Autor:
Simon Tazzyman, Georgia R. Stewart, James Yeomans, Adam Linford, Darren Lath, Joe Conner, Munitta Muthana, Andrew D. Chantry, Michelle A. Lawson
Publikováno v:
Viruses, Vol 15, Iss 3, p 603 (2023)
Multiple myeloma remains largely incurable due to refractory disease; therefore, novel treatment strategies that are safe and well-tolerated are required. Here, we studied the modified herpes simplex virus HSV1716 (SEPREHVIR®), which only replicates
Externí odkaz:
https://doaj.org/article/90bd4219e18b434d874154b6a60071e9
Autor:
Kavitha Chinnaiya, Michelle A. Lawson, Sally Thomas, Marie-Therese Haider, Jenny Down, Andrew D. Chantry, David Hughes, Antony Green, Jon R. Sayers, John A. Snowden, Martin P. Zeidler
Publikováno v:
Haematologica, Vol 102, Iss 9 (2017)
Externí odkaz:
https://doaj.org/article/c40f1dd8c0f64b22baa2be92f819adfa
Autor:
Spyros Kolovos, Guido Nador, Bhuvan Kishore, Matthew Streetly, Neil K. Rabin, Andrew D Chantry, Kwee Yong, John Ashcroft, Stella Bowcock, Mark T. Drayson, Karthik Ramasamy, Daniel Prieto-Alhambra, Cyrus Cooper, M. Kassim Javaid, Rafael Pinedo-Villanueva
Publikováno v:
Journal of Bone Oncology, Vol 17, Iss , Pp - (2019)
Background: Multiple myeloma (MM) is associated with high healthcare resource utilisation and increasing hospitalisation rates. The aim of this study was to characterise the hospital use by patients with MM in the English National Health Service (NHS
Externí odkaz:
https://doaj.org/article/40cc4ec1bc1845098331aed543e6dbe7
Autor:
Darren L Lath, Clive H Buckle, Holly R Evans, Matthew Fisher, Jenny M Down, Michelle A Lawson, Andrew D Chantry
Publikováno v:
PLoS ONE, Vol 13, Iss 6, p e0199517 (2018)
The receptor tyrosine kinase c-Met, its ligand HGF, and components of the downstream signalling pathway, have all been implicated in the pathogenesis of myeloma, both as modulators of plasma cell proliferation and as agents driving osteoclast differe
Externí odkaz:
https://doaj.org/article/d7a980be61d046e2969ca030891777b2
Autor:
Shivani Bhagoutie, Travis Sunil Beharry, Abigail A Bernard, K. S. Charles, Teria Bain, Habibah Saadia Baksh, Andrew D Chantry, Cristal Bernard
Publikováno v:
Transfusion Medicine. 31:339-349
OBJECTIVES To compare knowledge, attitudes and risk perception related to blood donation and transfusion in Trinidad and Tobago and Bahamas. BACKGROUND Trinidad and Tobago and the Bahamas are two Caribbean countries whose national blood transfusion s
Publikováno v:
Seminars in Cell & Developmental Biology. 112:49-58
Multiple myeloma is a bone marrow neoplasia with an incidence of 6/100,000/year in Europe. While the disease remains incurable, the development of novel treatments such as autologous stem cell transplantation, proteasome inhibitors and monoclonal ant
Autor:
John A. Snowden, Helen Jessop, Basil Sharrack, Andrew D Chantry, Lewis Kass-Iliyya, Alice Thorpe, Marios Hadjivassiliou, Ptolemaios G. Sarrigiannis
Publikováno v:
Journal of Neurology
Abstract Stiff Person Syndrome (SPS) is a rare immune-mediated disabling neurological disorder characterised by muscle spasms and high GAD antibodies. There are only a few case reports of autologous haematopoietic stem cell transplantation (auto-HSCT
Autor:
Michelle A. Lawson, Jennifer M. Down, Lisa J. Crawford, Dharminder Chauhan, Andrew D Chantry, Claudia Hamilton, Jonathan J. Morgan, Treen C. M. Morris, Krishnaraj Rajalingam, Alexandra E. Irvine, Roisin McAvera, Aswini Krishnan, David Campbell
Publikováno v:
Oncogene
Crawford, L J, Campbell, D C, Morgan, J J, Lawson, M A, Down, J M, Chauhan, D, McAvera, R M, Morris, T C, Hamilton, C, Krishnan, A, Rajalingam, K, Chantry, A D & Irvine, A E 2020, ' The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in Multiple Myeloma ', Oncogene, vol. 39, pp. 5001–5014 . https://doi.org/10.1038/s41388-020-1345-x
Crawford, L J, Campbell, D C, Morgan, J J, Lawson, M A, Down, J M, Chauhan, D, McAvera, R M, Morris, T C, Hamilton, C, Krishnan, A, Rajalingam, K, Chantry, A D & Irvine, A E 2020, ' The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in Multiple Myeloma ', Oncogene, vol. 39, pp. 5001–5014 . https://doi.org/10.1038/s41388-020-1345-x
Proteasome inhibitors have provided a significant advance in the treatment of multiple myeloma (MM). Consequently, there is increasing interest in developing strategies to target E3 ligases, de-ubiquitinases, and/or ubiquitin receptors within the ubi
Publikováno v:
Cancers, Vol 13, Iss 5687, p 5687 (2021)
Cancers
Cancers
Simple Summary Multiple myeloma is a type of blood cancer caused by the uncontrolled growth of antibody producing B cells (known as plasma cells) that reside in the bone marrow. It is classed as a largely incurable cancer as whilst patients respond w
Publikováno v:
Journal of Clinical Medicine
Journal of Clinical Medicine, Vol 10, Iss 3973, p 3973 (2021)
Journal of Clinical Medicine, Vol 10, Iss 3973, p 3973 (2021)
Lytic bone disease remains a life-altering complication of multiple myeloma, with up to 90% of sufferers experiencing skeletal events at some point in their cancer journey. This tumour-induced bone disease is driven by an upregulation of bone resorpt